Last 12 months
Inside the activity.
0 purchase rows · 35 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 2 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 16 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 17 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 05, 2017 Filed May 9, 2017 20:42 UTC |
Karachun Rita ASr. VP Fince-Global Controller
|
GrantRestricted Stock Unit · Derivative | 3,283 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009426 · doc4.xml · derivative · entry 3 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,283 Underlying: Common Stock · 3,283 shares Expires 2020-05-05 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| May 05, 2017 Filed May 9, 2017 20:42 UTC |
FRAZIER KENNETH CDirector · Chairman, President & CEO
|
GrantStock Option (right to buy) · Derivative | 534,950 | $0.00 Strike: $63.97 | $0.00 |
DisclosureSEC source: 0001225208-17-009427 · doc4.xml · derivative · entry 3 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 534,950 Underlying: Common Stock · 534,950 shares Expires 2027-05-04 F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/5/2018, 5/5/2019 and 5/5/2020. Read SEC document |
| May 05, 2017 Filed May 9, 2017 20:42 UTC |
PERLMUTTER ROGER MExe V-P & Pres, MRL
|
GrantStock Option (right to buy) · Derivative | 171,184 | $0.00 Strike: $63.97 | $0.00 |
DisclosureSEC source: 0001225208-17-009428 · doc4.xml · derivative · entry 2 PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,184 Underlying: Common Stock · 171,184 shares Expires 2027-05-04 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/5/2018, 5/5/2019 and 5/5/2020. Read SEC document |
| May 05, 2017 Filed May 9, 2017 20:42 UTC |
Schechter Adam HEVP & Pres-Global Human Health
|
GrantStock Option (right to buy) · Derivative | 162,625 | $0.00 Strike: $63.97 | $0.00 |
DisclosureSEC source: 0001225208-17-009429 · doc4.xml · derivative · entry 2 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,625 Underlying: Common Stock · 162,625 shares Expires 2027-05-04 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/5/2018, 5/5/2019 and 5/5/2020. Read SEC document |
| May 05, 2017 Filed May 9, 2017 20:42 UTC |
Holston Michael JEVP, General Counsel
|
GrantStock Option (right to buy) · Derivative | 94,151 | $0.00 Strike: $63.97 | $0.00 |
DisclosureSEC source: 0001225208-17-009430 · doc4.xml · derivative · entry 2 Holston Michael J · CIK 0001390613 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,151 Underlying: Common Stock · 94,151 shares Expires 2027-05-04 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/5/2018, 5/5/2019 and 5/5/2020. Read SEC document |
| May 05, 2017 Filed May 9, 2017 20:42 UTC |
Chattopadhyay SanatExe V-P & Pres. MMD
|
GrantStock Option (right to buy) · Derivative | 64,194 | $0.00 Strike: $63.97 | $0.00 |
DisclosureSEC source: 0001225208-17-009431 · doc4.xml · derivative · entry 2 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,194 Underlying: Common Stock · 64,194 shares Expires 2027-05-04 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/5/2018, 5/5/2019 and 5/5/2020. Read SEC document |
| May 05, 2017 Filed May 9, 2017 20:42 UTC |
DeLuca Richard R.EVP&Pres, Merck Animal Health
|
GrantStock Option (right to buy) · Derivative | 64,194 | $0.00 Strike: $63.97 | $0.00 |
DisclosureSEC source: 0001225208-17-009432 · doc4.xml · derivative · entry 3 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,194 Underlying: Common Stock · 64,194 shares Expires 2027-05-04 F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/5/2018, 5/5/2019 and 5/5/2020. Read SEC document |
| May 05, 2017 Filed May 9, 2017 20:42 UTC |
Gerberding Julie L.EVP Strat Comm, Gl Pub Policy
|
GrantStock Option (right to buy) · Derivative | 34,237 | $0.00 Strike: $63.97 | $0.00 |
DisclosureSEC source: 0001225208-17-009433 · doc4.xml · derivative · entry 2 Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,237 Underlying: Common Stock · 34,237 shares Expires 2027-05-04 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/5/2018, 5/5/2019 and 5/5/2020. Read SEC document |
| May 05, 2017 Filed May 9, 2017 20:42 UTC |
GRADDICK WEIR MIRIAN MExe V-P, HR
|
GrantStock Option (right to buy) · Derivative | 72,753 | $0.00 Strike: $63.97 | $0.00 |
DisclosureSEC source: 0001225208-17-009434 · doc4.xml · derivative · entry 2 GRADDICK WEIR MIRIAN M · CIK 0001168014 · Exe V-P, HR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,753 Underlying: Common Stock · 72,753 shares Expires 2027-05-04 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/5/2018, 5/5/2019 and 5/5/2020. Read SEC document |
| May 02, 2017 Filed May 3, 2017 13:52 UTC |
Gerberding Julie L.EVP Strat Comm, Gl Pub Policy
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,092 | $62.38 | $192,878.96 |
DisclosureSEC source: 0001225208-17-008903 · doc4.xml · derivative · entry 3 Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,092 shares Expires 2017-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| May 02, 2017 Filed May 3, 2017 13:52 UTC |
Gerberding Julie L.EVP Strat Comm, Gl Pub Policy
|
Tax withholdingCommon Stock | 1,078 | $62.38 | $67,245.64 |
DisclosureSEC source: 0001225208-17-008903 · doc4.xml · nonDerivative · entry 2 Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,338.348 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 02, 2017 Filed May 3, 2017 13:52 UTC |
Gerberding Julie L.EVP Strat Comm, Gl Pub Policy
|
Exercise / conversionCommon Stock | 3,092 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-008903 · doc4.xml · nonDerivative · entry 1 Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,416.348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2017 Filed May 3, 2017 13:54 UTC |
Chattopadhyay SanatExe V-P & Pres. MMD
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,092 | $62.38 | $192,878.96 |
DisclosureSEC source: 0001225208-17-008904 · doc4.xml · derivative · entry 3 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,092 shares Expires 2017-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| May 02, 2017 Filed May 3, 2017 13:54 UTC |
Chattopadhyay SanatExe V-P & Pres. MMD
|
Tax withholdingCommon Stock | 974 | $62.38 | $60,758.12 |
DisclosureSEC source: 0001225208-17-008904 · doc4.xml · nonDerivative · entry 2 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,662.548 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 02, 2017 Filed May 3, 2017 13:54 UTC |
Chattopadhyay SanatExe V-P & Pres. MMD
|
Exercise / conversionCommon Stock | 3,092 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-008904 · doc4.xml · nonDerivative · entry 1 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,636.548 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 03, 2017 Filed Apr 4, 2017 22:36 UTC |
Schechter Adam HEVP & Pres-Global Human Health
|
SaleCommon Stock | 53,850 | $63.48 | $3,418,166.45 |
DisclosureSEC source: 0001225208-17-007537 · doc4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 116,335.9747 F1 · kind: The sale reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.2600 to $63.6900, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 21:59 UTC |
GLOCER THOMAS HDirector
|
GrantPhantom Stock · Derivative | 511.4888 | $63.54 | $32,500.00 |
DisclosureSEC source: 0001225208-17-007499 · doc4.xml · derivative · entry 2 GLOCER THOMAS H · CIK 0001140799 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,802.5308 Underlying: Common Stock · 511.4888 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 21:59 UTC |
WEEKS WENDELL PDirector
|
GrantPhantom Stock · Derivative | 432.7982 | $63.54 | $27,500.00 |
DisclosureSEC source: 0001225208-17-007501 · doc4.xml · derivative · entry 2 WEEKS WENDELL P · CIK 0001206158 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,295.2282 Underlying: Common Stock · 432.7982 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 21:59 UTC |
LAZARUS ROCHELLE BDirector
|
GrantPhantom Stock · Derivative | 432.7982 | $63.54 | $27,500.00 |
DisclosureSEC source: 0001225208-17-007500 · doc4.xml · derivative · entry 3 LAZARUS ROCHELLE B · CIK 0001082206 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,816.6372 Underlying: Common Stock · 432.7982 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 21:59 UTC |
Wendell Peter CDirector
|
GrantPhantom Stock · Derivative | 432.7982 | $63.54 | $27,500.00 |
DisclosureSEC source: 0001225208-17-007502 · doc4.xml · derivative · entry 2 WENDELL PETER C · CIK 0001032635 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,285.8212 Underlying: Common Stock · 432.7982 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 21:46 UTC |
AMBROSE ADELE DSr.V-P & Chief Comuns Officer
|
GrantCommon Stock | 2,795 | $65.85 | $184,050.75 |
DisclosureSEC source: 0001225208-17-005081 · doc4.xml · nonDerivative · entry 1 AMBROSE ADELE D · CIK 0001182424 · Sr.V-P & Chief Comuns Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,937.015 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/14. Performance shares were paid out at 158 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2016. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 21:46 UTC |
Chattopadhyay SanatExe V-P & Pres. MMD
|
GrantCommon Stock | 3,758 | $65.85 | $247,464.30 |
DisclosureSEC source: 0001225208-17-005082 · doc4.xml · nonDerivative · entry 1 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,245.635 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/14. Performance shares were paid out at 158 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2016. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 21:46 UTC |
Davis Robert MEVP, Global Svcs & CFO
|
GrantCommon Stock | 31,913 | $65.85 | $2,101,471.05 |
DisclosureSEC source: 0001225208-17-005083 · doc4.xml · nonDerivative · entry 1 Davis Robert M · CIK 0001363076 · EVP, Global Svcs & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,913 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 5/9/14. Performance shares were paid out at 158 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2016. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 21:46 UTC |
DeLuca Richard R.EVP&Pres, Merck Animal Health
|
GrantCommon Stock | 11,771 | $65.85 | $775,120.35 |
DisclosureSEC source: 0001225208-17-005084 · doc4.xml · nonDerivative · entry 1 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,090.026 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/14. Performance shares were paid out at 158 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2016. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 21:46 UTC |
FRAZIER KENNETH CDirector · Chairman, President & CEO
|
GrantCommon Stock | 101,552 | $65.85 | $6,687,199.20 |
DisclosureSEC source: 0001225208-17-005085 · doc4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,304.063 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/14. Performance shares were paid out at 158 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2016. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 21:46 UTC |
Gerberding Julie L.EVP Strat Comm, Gl Pub Policy
|
GrantCommon Stock | 3,707 | $65.85 | $244,105.95 |
DisclosureSEC source: 0001225208-17-005086 · doc4.xml · nonDerivative · entry 1 Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,062.79 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/14. Performance shares were paid out at 158 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2016. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 21:46 UTC |
GRADDICK WEIR MIRIAN MExe V-P, HR
|
GrantCommon Stock | 16,995 | $65.85 | $1,119,120.75 |
DisclosureSEC source: 0001225208-17-005087 · doc4.xml · nonDerivative · entry 1 GRADDICK WEIR MIRIAN M · CIK 0001168014 · Exe V-P, HR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,484.319 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/14. Performance shares were paid out at 158 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2016. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 21:46 UTC |
Holston Michael JEVP, General Counsel
|
GrantCommon Stock | 12,159 | $65.85 | $800,670.15 |
DisclosureSEC source: 0001225208-17-005088 · doc4.xml · nonDerivative · entry 1 Holston Michael J · CIK 0001390613 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,439.227 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/14. Performance shares were paid out at 158 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2016. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 21:46 UTC |
PERLMUTTER ROGER MExe V-P & Pres, MRL
|
GrantCommon Stock | 32,670 | $65.85 | $2,151,319.50 |
DisclosureSEC source: 0001225208-17-005090 · doc4.xml · nonDerivative · entry 1 PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,601.221 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/14. Performance shares were paid out at 158 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2016. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 21:46 UTC |
Karachun Rita ASr. VP Fince-Global Controller
|
GrantCommon Stock | 2,797 | $65.85 | $184,182.45 |
DisclosureSEC source: 0001225208-17-005089 · doc4.xml · nonDerivative · entry 1 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,471.566 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/14. Performance shares were paid out at 158 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2016. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 21:46 UTC |
Schechter Adam HEVP & Pres-Global Human Health
|
GrantCommon Stock | 39,970 | $65.85 | $2,632,024.50 |
DisclosureSEC source: 0001225208-17-005091 · doc4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,970 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/14. Performance shares were paid out at 158 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2016. Read SEC document |
| February 27, 2017 Filed Apr 10, 2017 19:21 UTC Amendment |
Holston Michael JEVP, General Counsel
|
GrantCommon Stock | 11,312 | $65.85 | $744,895.20 |
DisclosureSEC source: 0001225208-17-007832 · doc4a.xml · nonDerivative · entry 1 Holston Michael J · CIK 0001390613 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,592.227 F1 · shares: The Amended Form 4 is being filed to correct an administrative error with regard to the number of shares withheld for payment of taxes on the 2/27/17 vesting of performance share units. The number of securities beneficially owned following the reported transaction should have been reported as 61,592.2270, and includes shares acquired in dividend reinvestment transactions. F1 · balance_after: The Amended Form 4 is being filed to correct an administrative error with regard to the number of shares withheld for payment of taxes on the 2/27/17 vesting of performance share units. The number of securities beneficially owned following the reported transaction should have been reported as 61,592.2270, and includes shares acquired in dividend reinvestment transactions. Read SEC document |
| February 27, 2017 Filed Apr 10, 2017 19:21 UTC Amendment |
Schechter Adam HEVP & Pres-Global Human Health
|
GrantCommon Stock | 37,758 | $65.85 | $2,486,364.30 |
DisclosureSEC source: 0001225208-17-007833 · doc4a.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,758 F1 · shares: The Amended Form 4 is being filed to correct an administrative error with regard to the number of shares withheld for payment of taxes on the 2/27/17 vesting of performance share units. The number of securities beneficially owned following the reported transaction should have been reported as 37,758.0000, and includes shares acquired in dividend reinvestment transactions. F1 · balance_after: The Amended Form 4 is being filed to correct an administrative error with regard to the number of shares withheld for payment of taxes on the 2/27/17 vesting of performance share units. The number of securities beneficially owned following the reported transaction should have been reported as 37,758.0000, and includes shares acquired in dividend reinvestment transactions. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 16:30 UTC |
Karachun Rita ASr. VP Fince-Global Controller
|
SaleCommon Stock | 2,954 | $64.73 | $191,226.60 |
DisclosureSEC source: 0001225208-17-003334 · doc4.xml · nonDerivative · entry 1 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,674.566 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 08, 2017 Filed Feb 9, 2017 17:52 UTC |
RUSSO PATRICIA FDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $35.19 | $0.00 |
DisclosureSEC source: 0001225208-17-002699 · doc4.xml · derivative · entry 3 RUSSO PATRICIA F · CIK 0001023219 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2020-08-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option became exercisable in equal installments on 8/4/2011, 8/4/2012 and 8/4/2013. Read SEC document |
| February 08, 2017 Filed Feb 9, 2017 17:52 UTC |
RUSSO PATRICIA FDirector
|
SaleCommon Stock | 5,000 | $64.42 | $322,121.00 |
DisclosureSEC source: 0001225208-17-002699 · doc4.xml · nonDerivative · entry 2 RUSSO PATRICIA F · CIK 0001023219 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,148 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.4200 to $64.4284, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| February 08, 2017 Filed Feb 9, 2017 17:52 UTC |
RUSSO PATRICIA FDirector
|
Exercise / conversionCommon Stock | 5,000 | $35.19 | $175,950.00 |
DisclosureSEC source: 0001225208-17-002699 · doc4.xml · nonDerivative · entry 1 RUSSO PATRICIA F · CIK 0001023219 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,148 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2017 Filed Mar 1, 2017 21:46 UTC |
FRAZIER KENNETH CDirector · Chairman, President & CEO
|
GiftCommon Stock | 10,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-005085 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 498,752.063 Read SEC document |
| February 06, 2017 Filed Feb 6, 2017 20:35 UTC |
WEEKS WENDELL PDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $51.86 | $0.00 |
DisclosureSEC source: 0001225208-17-002442 · doc4.xml · derivative · entry 3 WEEKS WENDELL P · CIK 0001206158 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2017-04-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option became exercisable in equal installments on 4/27/2008, 4/27/2009 and 4/27/2010. Read SEC document |
| February 06, 2017 Filed Feb 6, 2017 20:35 UTC |
WEEKS WENDELL PDirector
|
SaleCommon Stock | 5,000 | $64.51 | $322,541.50 |
DisclosureSEC source: 0001225208-17-002442 · doc4.xml · nonDerivative · entry 2 WEEKS WENDELL P · CIK 0001206158 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.5074 to $64.5100, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| February 06, 2017 Filed Feb 6, 2017 20:35 UTC |
WEEKS WENDELL PDirector
|
Exercise / conversionCommon Stock | 5,000 | $51.86 | $259,300.00 |
DisclosureSEC source: 0001225208-17-002442 · doc4.xml · nonDerivative · entry 1 WEEKS WENDELL P · CIK 0001206158 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2017 Filed Feb 6, 2017 20:35 UTC |
Cech Thomas RDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $35.19 | $0.00 |
DisclosureSEC source: 0001225208-17-002443 · doc4.xml · derivative · entry 3 Cech Thomas R · CIK 0001464680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2020-08-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option became exercisable in equal installments on 8/4/2011, 8/4/2012 and 8/4/2013. Read SEC document |
| February 03, 2017 Filed Feb 6, 2017 20:35 UTC |
Cech Thomas RDirector
|
SaleCommon Stock | 5,000 | $63.42 | $317,099.50 |
DisclosureSEC source: 0001225208-17-002443 · doc4.xml · nonDerivative · entry 2 Cech Thomas R · CIK 0001464680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.3800 to $63.4562, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| February 03, 2017 Filed Feb 6, 2017 20:35 UTC |
Cech Thomas RDirector
|
Exercise / conversionCommon Stock | 5,000 | $35.19 | $175,950.00 |
DisclosureSEC source: 0001225208-17-002443 · doc4.xml · nonDerivative · entry 1 Cech Thomas R · CIK 0001464680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2017 Filed Feb 6, 2017 20:35 UTC |
Schechter Adam HEVP & Pres-Global Human Health
|
Exercise / conversionStock Option (right to buy) · Derivative | 26,135 | $0.00 Strike: $33.49 | $0.00 |
DisclosureSEC source: 0001225208-17-002444 · doc4.xml · derivative · entry 6 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,135 shares Expires 2020-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option became exercisable in equal installments on 5/7/2011, 5/7/2012 and 5/7/2013. Read SEC document |
| February 03, 2017 Filed Feb 6, 2017 20:35 UTC |
Schechter Adam HEVP & Pres-Global Human Health
|
Exercise / conversionStock Option (right to buy) · Derivative | 10,200 | $0.00 Strike: $36.56 | $0.00 |
DisclosureSEC source: 0001225208-17-002444 · doc4.xml · derivative · entry 5 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,994 Underlying: Common Stock · 10,200 shares Expires 2021-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option became exercisable in equal installments on 5/4/2012, 5/4/2013 and 5/4/2014. Read SEC document |
| February 03, 2017 Filed Feb 6, 2017 20:35 UTC |
Schechter Adam HEVP & Pres-Global Human Health
|
SaleCommon Stock | 36,335 | $63.73 | $2,315,698.59 |
DisclosureSEC source: 0001225208-17-002444 · doc4.xml · nonDerivative · entry 3 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.3200 to $64.0300, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| February 03, 2017 Filed Feb 6, 2017 20:35 UTC |
Schechter Adam HEVP & Pres-Global Human Health
|
Exercise / conversionCommon Stock | 10,200 | $36.56 | $372,912.00 |
DisclosureSEC source: 0001225208-17-002444 · doc4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,335 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2017 Filed Feb 6, 2017 20:35 UTC |
Schechter Adam HEVP & Pres-Global Human Health
|
Exercise / conversionCommon Stock | 26,135 | $33.49 | $875,261.15 |
DisclosureSEC source: 0001225208-17-002444 · doc4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,135 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2017 Filed Feb 6, 2017 20:35 UTC |
Holston Michael JEVP, General Counsel
|
Exercise / conversionStock Option (right to buy) · Derivative | 36,680 | $0.00 Strike: $58.22 | $0.00 |
DisclosureSEC source: 0001225208-17-002445 · doc4.xml · derivative · entry 6 Holston Michael J · CIK 0001390613 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,341 Underlying: Common Stock · 36,680 shares Expires 2024-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option became exercisable in equal installments on 5/9/2015, 5/9/2016 and 5/9/2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.